GSK (LSE:GSK) has released third quarter figures that present a mixed picture. Sales reached £8,887 million, while net income declined to £1,543 million compared with £2,013 million a year earlier.
The latest figures landed alongside a sharp market reaction, with GSK's 1-day share price return falling 4.78% to £18.315, even though headlines have focused on new drug approvals and oncology data from Jemperli, Hibsago and the firm's antibody drug conjugate pipeline.
Short term momentum has softened, with the share price down 1.95% over the past week and 5.59% over 90 days. Long term holders have still seen an 8.26% 1-year total shareholder return and more than 40% total shareholder return over three and five years as the investment case has shifted toward specialty medicines and late stage assets.
Scan how GSK compares with other pharma groups being repriced on fresh trial data and regulatory decisions by reviewing 9 healthcare AI stocks in the same broader healthcare trend.
After a sharp £18.315 reset on solid results but softer vaccines, GSK now asks a simple question of you: step in after the wobble or wait for an even cheaper entry as the valuation case unfolds next.
Most Popular Narrative: 16% Undervalued
GSK's most followed narrative anchors fair value at £21.73, which sits well above the last close at £18.315 and frames the latest pullback as a valuation gap rather than a verdict on the whole business mix.
The main thing that has to go right is that GSK converts its enlarged late stage pipeline, particularly in oncology and long acting HIV and liver disease programs, into commercially meaningful products while delivering the planned £1.9b annual cost savings by 2029.
The current valuation implies investors are not fully crediting GSK for its stated >£40b 2031 sales outlook and the potential upside from oncology and long acting injectables, which is why this narrative describes the stock as undervalued and bullish.
See why 219 investors see GSK as 16% undervalued .
Result: Fair Value of £21.73 (UNDERVALUED)
Still, the GSK story can break if key HIV patents roll off before newer oncology and long acting injectables meaningfully contribute, or if pricing pressure in General Medicines deepens.
Find out about the key risks to this GSK narrative .
Next Steps
Mixed signals on GSK can create noise, so move fast, review the underlying data, and weigh both sides of the story yourself with 4 key rewards and 3 important warning signs .
Looking for more ideas beyond GSK?
If GSK has sharpened your focus on quality, now is the time to broaden your watchlist with a few targeted screens built around clear fundamentals.
-
Target quality at a discount by running through our list of 10 high quality undervalued stocks that combine strong financial traits with prices that have not fully caught up yet.
-
Zero in on cash flows and resilience by working through a list of solid balance sheet and fundamentals (10 results) that can help support you through different market conditions.
-
Aim ahead of the crowd by scanning 5 high quality undiscovered gems that pair robust fundamentals with relatively low investor attention today.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GSK.L .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
